-
Posted by
Two Blokes Jun 16 -
Filed in
Stock
-
8 views
Skyrizi and Rinvoq are rapidly replacing Humira, generating over $5 billion in Q1 2025 alone. From migraine to Parkinson's and obesity, AbbVie is building dominant franchises across multiple high-growth areas. With 42% operating margins, $20B in free cash flow, and a 3.4% dividend yield, AbbVie offers both growth and stability.
